Volume 224 - Issue 3
Antidepressant Prescribing in Australian Primary Care: Time to Reevaluate
Authors: Katharine A. Wallis, Joanna Moncrieff
Correspondence: k.wallis@uq.edu.au
Med J Aust 2026 || doi: 10.5694/mja2.70154
Published online: 3 March 2026
Published online: 3 March 2026
Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia
Lan Gao, Rosie Watson, Nawaf Yassi
Uptake and Costs of the 60-Day Dispensing Policy for Antihypertensive Medicines in Australia: A Mixed Methods Study
Tian Wang, Huy L. Nguyen, Isabella Tan, Dean S. Picone, Emily Atkins, Sonali R. Gnanenthiran, Michael O. Falster, Sallie-Anne Pearson, Anthony Rodgers, Aletta E. Schutte
Antidepressant Prescribing in Australian Primary Care: Time to Reevaluate
Gin S. Malhi, Erica Bell, Kinga Szymaniak, Philip M. Boyce, Jeffrey C. L. Looi
Valproate Prescribing for Female Adolescents and Management of the Associated Teratogenicity Risk, Royal Children's Hospital, Melbourne, 2022–2024: A Retrospective Audit of Medical Records Data
Briana Davis, Monica S. Cooper, Michael South, Jeremy L. Freeman, Emma Macdonald-Laurs
Medications for early treatment of COVID‐19 in Australia
Adam Polkinghorne, James M Branley
Nocebo effects in practice: methotrexate myths and misconceptions
Mark H Arnold, Jane Bleasel, Inam Haq